Therapeutic Drug Monitoring of Meropenem in Neonate with Necrotizing Enterocolitis: A Challenge

Abstract EN

Necrotizing enterocolitis (NEC) continues to be a major cause of neonatal morbidity and mortality.

We describe the added value of therapeutic drug monitoring by presenting the case of a preterm infant with severe NEC treated with meropenem.

Dosing strategy will achieve adequate patient outcome when treating pathogens with elevated MIC.

As safe as meropenem is, there are not enough data for 40 mg/kg, every 8 h infused over 4 h; accordingly, strict monitoring of blood levels is mandatory.

Based on our findings, a 4 h prolonged infusion of 40 mg/kg meropenem, every 8 h, will achieve an adequate patient outcome.